1. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib
   Lei Zhu et al, 2021, Cancer Research CrossRef
2. Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
   Ji Young Park et al, 2022, Tuberculosis and Respiratory Diseases CrossRef
3. Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations
   Giuseppe Pelosi et al, 2021, JTO Clinical and Research Reports CrossRef
4. Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
   Giulia Pasello et al, 2022, Frontiers in Oncology CrossRef
5. MYC expression and fatty acid oxidation in EGFR-TKI acquired resistance
   GuoSheng Wang et al, 2024, Drug Resistance Updates CrossRef
6. Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
   Weigang Xiu et al, 2021, Frontiers in Oncology CrossRef
7. Acquired resistance mechanisms to osimertinib: The constant battle
   Ziad Zalaquett et al, 2023, Cancer Treatment Reviews CrossRef
8. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
   Gee-Chen Chang et al, 2024, PLOS ONE CrossRef